Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wahl, R. L.
Right arrow Articles by Mudgett, E. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wahl, R. L.
Right arrow Articles by Mudgett, E. E.

Radiology, Vol 179, 765-770, Copyright © 1991 by Radiological Society of North America

ARTICLES

Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy- D-glucose

RL Wahl, RL Cody, GD Hutchins and EE Mudgett
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0028.

The authors assessed whether breast cancers can be detected by means of positron emission tomography (PET) with the positron-emitter-labeled glucose analogue 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG). In 12 patients with primary and/or metastatic breast cancer, PET images of F- 18 distribution in vivo were obtained approximately 1 hour after intravenous injection of 10 mCi of FDG. Scan findings were correlated with other imaging data and physical examination and biopsy results. Ten of 10 primary breast cancers were imaged by means of FDG PET with a tumor:background FDG uptake ratio of 8.1 (median). Ten of 10 bone metastases were imaged with a tumor:normal bone uptake ratio of 6.05 (median). Five of five known soft-tissue metastases and four previously unsuspected nodal lesions were found with PET. No false-positive foci of FDG uptake were demonstrated. In two cases with negative mammograms due to dense breast parenchyma, FDG PET clearly delineated the primary tumors. These preliminary data demonstrate the feasibility and substantial potential of PET scanning with FDG to detect and localize both primary and metastatic breast cancers.


This article has been cited by other articles:


Home page
 RadiologyHome page
D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir
Molecular Imaging Techniques in Body Imaging
Radiology, November 1, 2007; 245(2): 333 - 356.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. Kumar, N. Lal, and A. Alavi
18F-FDG PET in Detecting Primary Breast Cancer
J. Nucl. Med., October 1, 2007; 48(10): 1751 - 1751.
[Full Text] [PDF]

Home page
 JNMHome page
A. Mavi, T. F. Cermik, M. Urhan, H. Puskulcu, S. Basu, J. Q. Yu, H. Zhuang, B. Czerniecki, and A. Alavi
The Effects of Estrogen, Progesterone, and C-erbB-2 Receptor States on 18F-FDG Uptake of Primary Breast Cancer Lesions
J. Nucl. Med., August 1, 2007; 48(8): 1266 - 1272.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend
PET/CT: Form and Function
Radiology, February 1, 2007; 242(2): 360 - 385.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Couturier, G. Jerusalem, J.-M. N'Guyen, and R. Hustinx
Sequential Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Response to Chemotherapy in Metastatic Breast Cancer.
Clin. Cancer Res., November 1, 2006; 12(21): 6437 - 6443.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. Mavi, M. Urhan, J. Q. Yu, H. Zhuang, M. Houseni, T. F. Cermik, D. Thiruvenkatasamy, B. Czerniecki, M. Schnall, and A. Alavi
Dual Time Point 18F-FDG PET Imaging Detects Breast Cancer with High Sensitivity and Correlates Well with Histologic Subtypes
J. Nucl. Med., September 1, 2006; 47(9): 1440 - 1446.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. R. Port, H. Yeung, M. Gonen, L. Liberman, J. Caravelli, P. Borgen, and S. Larson
18F-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Scanning Affects Surgical Management in Selected Patients With High-Risk, Operable Breast Carcinoma
Ann. Surg. Oncol., May 1, 2006; 13(5): 677 - 684.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
H. Nomori, K. Watanabe, T. Ohtsuka, T. Naruke, K. Suemasu, T. Kobayashi, and K. Uno
Fluorine 18-tagged fluorodeoxyglucose positron emission tomographic scanning to predict lymph node metastasis, invasiveness, or both, in clinical T1 N0 M0 lung adenocarcinoma
J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 396 - 401.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
P. J. Lovrics, V. Chen, G. Coates, S. D. Cornacchi, C. H. Goldsmith, C. Law, M. N. Levine, K. Sanders, and V. R. Tandan
A Prospective Evaluation of Positron Emission Tomography Scanning, Sentinel Lymph Node Biopsy, and Standard Axillary Dissection for Axillary Staging in Patients with Early Stage Breast Cancer
Ann. Surg. Oncol., September 1, 2004; 11(9): 846 - 853.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Hamaoka, J. E. Madewell, D. A. Podoloff, G. N. Hortobagyi, and N. T. Ueno
Bone Imaging in Metastatic Breast Cancer
J. Clin. Oncol., July 15, 2004; 22(14): 2942 - 2953.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
E. M. Rohren, T. G. Turkington, and R. E. Coleman
Clinical Applications of PET in Oncology
Radiology, May 1, 2004; 231(2): 305 - 332.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J.M. van der Hoeven, N. C. Krak, O. S. Hoekstra, E. F.I. Comans, R. P.A. Boom, D. van Geldere, S. Meijer, E. van der Wall, J. Buter, H. M. Pinedo, et al.
18F-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging of Locally Advanced Breast Cancer
J. Clin. Oncol., April 1, 2004; 22(7): 1253 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. L. Wahl, B. A. Siegel, R. E. Coleman, and C. G. Gatsonis
Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study Group
J. Clin. Oncol., January 15, 2004; 22(2): 277 - 285.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. L. Wahl
Why Nearly All PET of Abdominal and Pelvic Cancers Will Be Performed as PET/CT
J. Nucl. Med., January 1, 2004; 45(90010): 82S - 95.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. A. Mankoff, L. K. Dunnwald, and P. Kinahan
Are We Ready for Dedicated Breast Imaging Approaches?
J. Nucl. Med., April 1, 2003; 44(4): 594 - 595.
[Full Text] [PDF]

Home page
 RadioGraphicsHome page
L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith
Clinical Role of FDG PET in Evaluation of Cancer Patients
RadioGraphics, March 1, 2003; 23(2): 315 - 340.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H.-J. Jeong, J.-K. Chung, Y. K. Kim, C. Y. Kim, D. G. Kim, J. M. Jeong, D. S. Lee, H. W. Jung, and M. C. Lee
Usefulness of Whole-Body 18F-FDG PET in Patients with Suspected Metastatic Brain Tumors
J. Nucl. Med., November 1, 2002; 43(11): 1432 - 1437.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
C.-S. Liu, Y.-Y. Shen, C.-C. Lin, R.-F. Yen, and C.-H. Kao
Clinical Impact of [18F]FDG-PET in Patients with Suspected Recurrent Breast Cancer Based on Asymptomatically Elevated Tumor Marker Serum Levels: a Preliminary Report
Jpn. J. Clin. Oncol., July 1, 2002; 32(7): 244 - 247.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
J. Y. Charvolin, R. J. Salmon, A. Pecking, and V. Mareschal
Positron Emission Tomography Detection of Breast Cancer Metastasis to the Uterus
Obstet. Gynecol., May 1, 2002; 99(5): 915 - 917.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. Vranjesevic, J. E. Filmont, J. Meta, D. H. Silverman, M. E. Phelps, J. Rao, P. E. Valk, and J. Czernin
Whole-Body 18F-FDG PET and Conventional Imaging for Predicting Outcome in Previously Treated Breast Cancer Patients
J. Nucl. Med., March 1, 2002; 43(3): 325 - 329.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. Higashi, T. Saga, Y. Nakamoto, T. Ishimori, M. H. Mamede, M. Wada, R. Doi, R. Hosotani, M. Imamura, and J. Konishi
Relationship Between Retention Index in Dual-Phase 18F-FDG PET, and Hexokinase-II and Glucose Transporter-1 Expression in Pancreatic Cancer
J. Nucl. Med., February 1, 2002; 43(2): 173 - 180.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Greco, F. Crippa, R. Agresti, E. Seregni, A. Gerali, R. Giovanazzi, A. Micheli, S. Asero, C. Ferraris, M. Gennaro, et al.
Axillary Lymph Node Staging in Breast Cancer by 2-Fluoro-2-deoxy-D-glucose-Positron Emission Tomography: Clinical Evaluation and Alternative Management
J Natl Cancer Inst, April 18, 2001; 93(8): 630 - 635.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J.-H. Yang, S. J. Nam, T. S. Lee, H. K. Lee, S. H. Jung, and B. T. Kim
Comparison of Intraoperative Frozen Section Analysis of Sentinel Node with Preoperative Positron Emission Tomography in the Diagnosis of Axillary Lymph Node Status in Breast Cancer Patients
Jpn. J. Clin. Oncol., January 1, 2001; 31(1): 1 - 6.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
N. Avril, M. Menzel, J. Dose, M. Schelling, W. Weber, F. Janicke, W. Nathrath, and M. Schwaiger
Glucose Metabolism of Breast Cancer Assessed by 18F-FDG PET: Histologic and Immunohistochemical Tissue Analysis
J. Nucl. Med., January 1, 2001; 42(1): 9 - 16.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Avril, C. A. Rose, M. Schelling, J. Dose, W. Kuhn, S. Bense, W. Weber, S. Ziegler, H. Graeff, and M. Schwaiger
Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and Limitations
J. Clin. Oncol., October 20, 2000; 18(20): 3495 - 3502.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Schelling, N. Avril, J. Nahrig, W. Kuhn, W. Romer, D. Sattler, M. Werner, J. Dose, F. Janicke, H. Graeff, et al.
Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer
J. Clin. Oncol., April 1, 2000; 18(8): 1689 - 1695.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
K. Murthy, M. Aznar, A. M. Bergman, C. J. Thompson, J. L. Robar, R. Lisbona, A. Loutfi, and J. H. Gagnon
Positron Emission Mammographic Instrument: Initial Results
Radiology, April 1, 2000; 215(1): 280 - 285.
[Abstract] [Full Text]

Home page
 RadiologyHome page
P. B. Hathaway, D. A. Mankoff, K. R. Maravilla, M. M. Austin-Seymour, G. K. Ellis, J. R. Gralow, A. A. Cortese, C. E. Hayes, and R. E. Moe
Value of Combined FDG PET and MR Imaging in the Evaluation of Suspected Recurrent Local-Regional Breast Cancer: Preliminary Experience
Radiology, March 1, 1999; 210(3): 807 - 814.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1991 by the Radiological Society of North America.